Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2019
The 9th European Lung Cancer Conference
Geneva, Switzerland - 10 Apr - 13 Apr 2019
Presentation Date(s):- 10 Apr - 13 Apr 2019
- Total Presentations: 489
-
+
Proffered Paper session I
- Type: Proffered Paper session
- Presentations: 8
- Coordinates: 4/10/2019, 16:30 - 18:15, Room C
-
+
LBA4 - Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study
17:45 - 18:00 | Presenter: Niels Reinmuth
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Proffered Paper session II
- Type: Proffered Paper session
- Presentations: 8
- Coordinates: 4/11/2019, 09:00 - 10:30, Room A
-
+
109O - Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
09:39 - 09:51 | Presenter: Fabrice Barlesi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ESMO-IASLC Best Abstracts
- Type: Proffered Paper session
- Presentations: 7
- Coordinates: 4/11/2019, 14:45 - 16:15, Room B
-
+
LBA3 - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC
15:00 - 15:15 | Presenter: Byoung Chul Cho
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
102O - Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC
15:30 - 15:45 | Presenter: Tony S.K. Mok
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.